# N4 Pharma EPO has now formally granted European Patent

- Link: https://www.directorstalkinterviews.com/n4-pharma-epo-has-now-formally-granted-european-patent/4121025965
- Published: 2021-10-01T07:07:08+01:00
- Author: Giles

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
®, a novel delivery system for cancer treatments and vaccines, has announced that
further to the Company’s announcement dated 11 February 2021 in which it was stated
that the European Patent Office (“EPO”) had notified the Company of its intention
to grant a European patent in relation to Nuvec® specifically in respect of its 
composition, particulate materials and methods for making the particulate materials,
the EPO has now granted this Patent which has been validated in the main territories
across Europe*. This Patent adds to existing grants in Australia and Japan.

The Company is also pleased to announce that it has been informed by the Chinese
Patent Office (“CPO”) of its intention to grant the Patent in China in relation 
to Nuvec®.

Discussions with other key patent authorities in the US, Canada and India are continuing
and updates will be provided by the Company on these in due course.

> **Nigel Theobald, Chief Executive Officer of N4 Pharma, commented **: “We are 
> delighted that the EPO has now formally granted the European Patent which is now
> validated across Europe. This achieves another key step in our IP strategy where
> we are also making excellent progress following the notice of allowance made recently
> by the CPO for the potentially huge market of China and the ongoing discussions
> in other key jurisdictions. We look forward to updating the market on these in
> due course.”

The information contained within this announcement is deemed by the Company to constitute
inside information as stipulated under the Market Abuse Regulations (EU) No. 596/
2014 which has been incorporated into UK law by the European Union (Withdrawal) 
Act 2018.  Upon the publication of this announcement via Regulatory Information 
Service, this inside information is now considered to be in the public domain.

*European territories validated are: United Kingdom, France, Germany, Spain, Italy,
Netherlands, Switzerland, Sweden, Denmark, Ireland, Malta, Belgium, Portugal, Norway,
Poland  

Share on: